Search Results - "Fokas E"

Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Authors: Hofheinz, R.-D. Fokas, E. Benhaim, L. et al.

Source: Annals of Oncology. Sep2025, Vol. 36 Issue 9, p1007-1024. 18p.

Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.

Authors: Williams, H. Fokas, E. Diefenhardt, M. et al.

Source: Annals of Oncology. May2025, Vol. 36 Issue 5, p543-547. 5p.

OC-0273 Quality of life following TNT of rectal cancer in the CAO/ARO/AIO-12 phase 2 trial.

Authors: Kosmala, R. Fokas, E. Salazar Hammann, A. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS208-S209. 2p.

Subjects: Rectal cancer, Quality of life

Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.

Authors: Fokas, E Fietkau, R Hartmann, A et al.

Source: Annals of Oncology. Jul2018, Vol. 29 Issue 7, p1521-1527. 7p. 3 Charts, 1 Graph.

SP-0362 Rectum: Does chemotherapy intensification improve tumour response more than radiotherapy does?

Authors: Fokas, E. (AUTHOR)

Source: Radiotherapy & Oncology. 2022 Supplement 1, Vol. 170, pS308-S308. 1p.

Subjects: Rectum, Radiotherapy, Cancer chemotherapy, Tumors

OC-0501 Chemo-RT plus induction or consolidation chemotherapy for rectal cancer: a randomised phase 2 trial.

Authors: Fokas, E. Allgäuer, M. Polat, B. et al.

Source: Radiotherapy & Oncology. 2019 Supplement 1, Vol. 133, pS257-S258. 2p.

Subjects: Rectal cancer, Cancer chemotherapy

OC-0384 QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04).

Authors: Kosmala, R. Fokas, E. Flentje, M. et al.

Source: Radiotherapy & Oncology. 2019 Supplement 1, Vol. 133, pS191-S192. 2p.

Subjects: Rectal cancer treatment, Combined modality therapy

SP-0503: The total neoadjuvant approach: when and where to add chemotherapy in rectal cancer.

Authors: Fokas, E. (AUTHOR)

Source: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS279-S279. 1p.

Subjects: Rectal cancer, Cancer chemotherapy

Early image acquisition ⁶⁸Ga-FAPI-46-PET/CT in prone position is promising in the workup of rectosigmoid and anal carcinoma.

Authors: Ufton, D. Heilinger, J. Weis, H. et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jan2026, Vol. 53 Issue 2, p748-752. 5p.

Reply to the Letter to the Editor by Perez et al. regarding "Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials"

Authors: Garcia-Aguilar, J. Williams, H. Fokas, E. et al.

Source: Annals of Oncology. Jun2025, Vol. 36 Issue 6, p705-706. 2p.

O-011 - Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12.

Authors: Hofheinz, R. Fokas, E. Allgäuer, M. et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv129-iv129. 1p.

SP-0470: Does radiotherapy still have a role in the management of pancreatic cancer?

Authors: Fokas, E.

Source: Radiotherapy & Oncology. May2017 Supplement 1, Vol. 123, pS249-S250. 1p.

PV-0325: Tumor Regression Grading in the CAO/ARO/AIO-04 phase 3 trial in locally advanced rectal carcinoma.

Authors: Fokas, E. Ghadimi, M. Fietkau, R. et al.

Source: Radiotherapy & Oncology. May2017 Supplement 1, Vol. 123, pS170-S171. 1p.

PD-0609: A comparison of 4 target volume definitions for pancreatic cancer: 2 with and 2 without lymphatics.

Authors: Fokas, E. Eccles, C. Patel, N. et al.

Source: Radiotherapy & Oncology. Mar2013 Supplement 2, Vol. 106, pS235-S236. 1p.

Subjects: Pancreatic cancer diagnosis, Cancer patients, Pancreatic cancer, Pancreatic cancer treatment, Lymphatic physiology, Radiation dosimetry

SP-0421 SYNTHETIC LETHAL APPROACHES TO USING DRUGS WITH RADIATION

Authors: McKenna, W.G. Fokas, E. Kelly, C. et al.

Source: Radiotherapy & Oncology. May2012 Supplement, Vol. 103 Issue s1, pS168-S168. 1p.

365 THE TUMOUR MICROENVIRONMENT IN COMBINED MODALITY THERAPY

Authors: McKenna, W.G. Fokas, E. Qayum, N. et al.

Source: Radiotherapy & Oncology. Mar2012, Vol. 102, pS187-S188. 0p.

A Comparison of 4 Target Volume Definitions for Pancreatic Cancer: Two Concepts Including the Lymphatics (RTOG and ARO) and 2 Concepts Only Treating the Primary Tumor (Michigan and UK-SCALOP)

Authors: Brunner, T. Fokas, E. Eccles, C.L. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Nov2012 Supplement, Vol. 84, pS322-S322. 1p.

SP-0106: Dual targeting of pi3k/mTOR.

Authors: Fokas, E.

Source: Radiotherapy & Oncology. 2014 Supplement, Vol. 111, pS43-S43. 1p.

Subjects: mTOR protein, Protein kinases, Targeted drug delivery, Radiotherapy, Dosage forms of drugs

Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.

Authors: Hofheinz, R -D Arnold, D Fokas, E et al.

Source: Annals of Oncology. Aug2018, Vol. 29 Issue 8, p1793-1799. 7p. 2 Charts, 3 Graphs.

Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.

Authors: Wang LF Fokas E Juricko J et al.

Source: BMC Cancer. 2008, Vol. 8, p79-79. 1p.